BRAF-Mutant Melanoma

Oncogenomics ◽

10.1016/b978-0-12-811785-9.00046-6 ◽

2019 ◽

pp. 655-668

Author(s):

Svenja Meierjohann ◽

Bastian Schilling

Keyword(s):

Download Full-text

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

Case Medical Research ◽

10.31525/ct1-nct03898908 ◽

2019 ◽

Author(s):

Keyword(s):

Local Treatment ◽

The Brain ◽

Download Full-text

Faculty Opinions recommendation of Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725253315.793521072 ◽

2016 ◽

Author(s):

Ashani Weeraratna

Keyword(s):

Combination Therapy ◽

Metastatic Melanoma ◽

Download Full-text

Faculty Opinions recommendation of Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725773106.793510004 ◽

2015 ◽

Author(s):

Jian-Jun Wei ◽

Wen Zhou

Keyword(s):

Download Full-text

Faculty Opinions recommendation of A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737579464.793576031 ◽

2020 ◽

Author(s):

Susanne Muehlich ◽

Melanie Meier

Keyword(s):

Mapk Pathway ◽

Feed Forward ◽

Download Full-text

Multidisciplinary Care of BRAF ‐Mutant Stage III Melanoma: A Physicians Perspective Review

The Oncologist ◽

10.1002/onco.13852 ◽

2021 ◽

Author(s):

Lynn A. Cornelius ◽

Ryan C. Fields ◽

Ahmad Tarhini

Keyword(s):

Multidisciplinary Care ◽

Stage Iii ◽

Stage Iii Melanoma ◽

Download Full-text

Edoxaban prevented adverse effects including pyrexia and elevation of D‐dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF‐mutant melanoma

The Journal of Dermatology ◽

10.1111/1346-8138.15813 ◽

2021 ◽

Author(s):

Kei Mukai ◽

Masahiro Kamata ◽

Mirei Miyazaki ◽

Mayumi Nagata ◽

Saki Fukaya ◽

...

Keyword(s):

Adverse Effects ◽

Mek Inhibitors ◽

Braf Mutant ◽

Download Full-text

Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia

British Journal of Cancer ◽

10.1038/s41416-021-01339-4 ◽

2021 ◽

Author(s):

Alexandra M. Kane ◽

Cheng Liu ◽

Lochlan J. Fennell ◽

Diane M. McKeone ◽

Catherine E. Bond ◽

...

Keyword(s):

Clinical Study ◽

Colorectal Neoplasia ◽

Download Full-text

BRAF-Mutant Metastatic Melanoma Presenting as a Fungating Soft Tissue Mass Suspicious for Sarcoma

Operative Techniques in Orthopaedics ◽

10.1016/j.oto.2020.100804 ◽

2020 ◽

Vol 30 (2) ◽

pp. 100804

Author(s):

Stephen Chen ◽

Stella J. Lee

Keyword(s):

Soft Tissue ◽

Metastatic Melanoma ◽

Soft Tissue Mass ◽

Tissue Mass ◽

Download Full-text

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

OncoImmunology ◽

10.1080/2162402x.2015.1052212 ◽

2015 ◽

Vol 5 (7) ◽

pp. e1052212 ◽

Author(s):

Blanca Homet Moreno ◽

Stephen Mok ◽

Begonya Comin-Anduix ◽

Siwen Hu-Lieskovan ◽

Antoni Ribas

Keyword(s):

Combined Treatment ◽

Download Full-text

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

Clinical & Translational Oncology ◽

10.1007/s12094-015-1438-0 ◽

2015 ◽

Vol 18 (8) ◽

pp. 848-858 ◽

Author(s):

O. Abdel-Rahman ◽

H. ElHalawani ◽

H. Ahmed

Keyword(s):

Meta Analysis ◽

Single Agent ◽

Advanced Melanoma ◽

Published Data ◽

Mek Inhibition ◽

Braf Inhibition ◽

Download Full-text